Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz May Turn To Novartis Sales Force For Omnitrope Marketing

This article was originally published in The Pink Sheet Daily

Executive Summary

Sandoz' follow-on human growth hormone cleared FDA May 30, but the agancy asserts that the approval does not create a biosimilar regulatory pathway.

You may also be interested in...



Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY

In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.

Sandoz VP-Biopharma Development Ajaz Hussain: An Interview With “The Pink Sheet” DAILY

In the wake of Omnitrope’s approval in the U.S. and Europe, Sandoz is moving forward with a robust biosimilar pipeline.

Just A Product, Not A Pathway, FDA Says Of Omnitrope Approval

Sandoz' follow-on human growth hormone does not establish a precedent for follow-on proteins for biologics regulated under the Public Health Service Act.

Related Content

Topics

UsernamePublicRestriction

Register

PS064258

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel